Archive

New Speciality Pharma Customer for new Indication

Physiomics plc is pleased to announce that it has signed a new contract with another new speciality pharma customer, to perform PK/PD modelling analysis for…

Final Results for the year ended 30 June 2015

Chairman’s Statement  Summary of Results in the year ended 30 June 2015 •    The turnover of the Company was £235,486 (2014: £267,903). •    The operating loss reduced…

Strategic Update

Physiomics is pleased to provide an update on its strategic direction. For some time the Company has been pursuing M&A targets, in particular oncology…

4th Large Pharma Customer for Virtual Tumour

Physiomics is pleased to announce that it has signed a new Virtual Tumour deal with a new pharmaceutical company, the 4th large pharma customer…

Update: 5th extension project to advance oncology candidate with global pharma company

Physiomics is pleased to announce that it has signed a further extension to a Virtual Tumour project with a major global pharmaceutical company, first announced…

Professor Mark Middleton appointed to Physiomics SAB

Physiomics plc is pleased to announce that it has appointed Professor Mark Middleton to its Scientific Advisory Board. Professor Middleton is Professor of Experimental…

Workshop on Applications of Physiomics’ Virtual Tumour to Immunotherapy and Translational Science- June 2, 2015, Hersonissos (Greece)

Physiomics will present a half-day workshop on “Applications of Physiomics’ Virtual Tumour to Immunotherapy and Translational Science”, ahead of the 2015 PAGE meeting. This…

Dr Hugues Dolgos, Merck Serono, presenting at QSP meeting today

Dr Hugues Dolgos, Global Head, Quantitative Pharmacology & Drug Disposition, Merck Serono, is presenting at the Quantitative Systems Pharmacology meeting today in Basel,…

Physiomics to present new developments of the Virtual Tumour platform in immunotherapy at AACR Annual Meeting 2015

Physiomics plc is pleased to announce that it is participating in the American Association for Cancer Research Annual Meeting 2015, taking place at the Pennsylvania…

First contract for a clinical version of our Virtual Tumour model (“Virtual Tumour Clinical”) with Global Pharmaceutical Company, Merck (Merck Serono)

Physiomics plc is pleased to announce that it has signed its first contract for developing Virtual Tumour Clinical with a global pharmaceutical company. The client…